Method of inhibiting the growth of Salmonella

Inventors

Dastych, Jaroslaw • Dziadek, Jaroslaw • Gorecka, Elzbieta • Rumijowska-Galewicz, Anna • Wojtasik, Arkadiusz • Wojcik, Ewelina

Assignees

Proteon Pharmaceuticals SA

Abstract

Method of inhibiting the growth of Salmonella in a chicken, comprising administering at least one strain of bacteriophage that lyses at least one Salmonella serovar to a chicken in need thereof, wherein the at least one strain of bacteriophage is a strain selected from PCM F/00069 (strain 8sent1748), PCM F/00070 (strain 8sent65) and PCM F/00071 (strain 3sent1).

Core Innovation

The document describes an antibiotic-free feed additive approach for inhibiting the growth of Salmonella in a chicken by administering at least one strain of bacteriophage that lyses at least one Salmonella serovar. The method is based on a selection of deposited bacteriophage strains identified as PCM F/00069 (strain 8sent1748), PCM F/00070 (strain 8sent65), and PCM F/00071 (strain 3sent1).

The document further describes phage screening and selection using multi-well plates and resazurin readout to assess in vitro lytic activity and phage titre and lytic strength. It also describes phage propagation and purification concepts for phage production, including bioreactor-scale production, concentration and filtration, and an optional microencapsulation approach.

In addition, the document states safety and efficacy evidence, including endotoxin testing and cytotoxicity testing, and in vivo broiler challenge results showing reduced Salmonella detection and an approximately 200-fold reduction in infection level one week after stopping phage dosing. The document also states that phages are not detected in internal organs and that phage detection decreases after cessation of treatment.

Claims Coverage

The partial content provides one independent claim describing a method for inhibiting Salmonella growth in a chicken using at least one bacteriophage strain selected from three specifically identified deposited strains. The claim coverage includes additional inventive features specified in dependent claim excerpts, including multiple strains, composition administration, and microencapsulated dosage form.

Across the independent claim and the provided dependent-claim excerpts, the inventive core is administering bacteriophages that lyse Salmonella serovars to chickens, using specifically identified deposited phage strains and, in refinements, administering multiple strains, delivering the phages in a composition, and optionally formulating the composition as microencapsulated dosage form.

Stated Advantages

Documented Applications